Effect of Induction and Maintenance of Anesthesia With Etomidate on Hemodynamics and Oxidative Stress in Diabetic Patients
Information source: Zhujiang Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hemodynamics; Oxidative Stress; Anesthesia
Intervention: midazolam (Drug); Penehyclidine Hydrochloride Injection (Drug); Etomidate (Drug); Propofol (Drug); Fentanyl (Drug); Cisatracurium Besilate (Drug); Remifentanil (Drug); Sevoflurane (Drug)
Phase: Phase 4
Status: Not yet recruiting
Sponsored by: Zhujiang Hospital
Summary
To explore the effect of induction and maintenance of anesthesia with etomidate on
hemodynamics and oxidative stress in diabetic patients.
Clinical Details
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Mean arterial pressureCentral venous pressure Heart rate Respiratory rate Oxygen saturation Blood glucose Insulin
Secondary outcome: Super oxide dismutaseGlutathione Xanthine oxidase
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Aged between 18 and 65 years;
- Diabetic patients preparing for elective surgery;
- Body mass index is between 16 and 30 kg/m2;
- Blood glucose is under 8. 3 mmol/kg by oral antidiabetic agents or diet control;
- American Society of Anesthesiology (ASA) Physical Status: Ⅰ or Ⅱ;
- Expected operation duration is between 2 and 8 h;
- Signed informed consent form.
Exclusion Criteria:
- Severe cardiac, cerebral, liver, kidney, lung, endocrine disease or infectious
disease;
- Chemotherapy or immunotherapy before the surgery;
- Allergy to trial drug or other contraindication;
- Expected or history of difficult airway;
- Suspected abuse of narcotic analgesia;
- Diseases of neuromuscular system;
- Mentally unstable or has a mental illness;
- Trend of malignant hyperthermia;
- Pregnant or breast-feeding women;
- Attendance of other trial past 30 days.
Locations and Contacts
Additional Information
Starting date: September 2014
Last updated: July 24, 2014
|